The P450 epoxygenase pathway metabolizes arachidonic acid (AA) into eicosanoid metabolites referred to as epoxyeicosatrienoic acids (EETs). EETs are produced in brain and perform important functions, including protection of neurons from ischemic injury. The major regio-isomer of EETs produced in brain and astrocytes is 14,15-EET. However, 14,15-EET is a preferred substrate for the soluble epoxide hydrolase (sEH), which metabolizes EETs into less active hydration products called dihydroxyeicosatrienoic acids (DHETs). Therefore, in the current proposal, we will test the hypothesis that sEH inhibition, effectively prolonging the half-life of 14,15-EET, is protective against ischemic brain injury in vivo. We will use selective inhibitors of sEH and sEH knockout (sEHKO) mice to determine if sEH inactivation reduces tissue damage and improves functional recovery after MCA occlusion (MCAO). We will combine EETs measurements in brain with pharmacological inhibitors of EETs synthesis and action in order to link protection acquired by sEH inactivation specifically to 14,15-EET. Furthermore, we will determine the cellular localization and effects of ischemia on the level and regional and subcellular distribution of sEH in ischemic brain. Finally, we will determine if neuroprotection by 14,15-EET is mediated in part via its action on putative membrane- associated receptor to specifically activate G-protein G alpha-s, leading to increased phosphorylation of cAMP-response element binding protein (CREB) and enhanced CRE-dependent gene transcription. The proposed studies are novel in that the pathophysiological role of sEH in cerebral ischemia has not been previously examined. The studies are also clinically relevant, and represent the first evaluation of a new class of sEH inhibitors as neuroprotective agents against brain damage after stroke.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-L (90))
Program Officer
Bosetti, Francesca
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
Schools of Medicine
United States
Zip Code
Davis, Catherine M; Liu, Xuehong; Alkayed, Nabil J (2017) Cytochrome P450 eicosanoids in cerebrovascular function and disease. Pharmacol Ther 179:31-46
Jia, Jia; Davis, Catherine M; Zhang, Wenri et al. (2016) Sex- and isoform-specific mechanism of neuroprotection by transgenic expression of P450 epoxygenase in vascular endothelium. Exp Neurol 279:75-85
Nelson, Jonathan W; Das, Anjali J; Barnes, Anthony P et al. (2016) Disrupting Dimerization Translocates Soluble Epoxide Hydrolase to Peroxisomes. PLoS One 11:e0152742
Siler, Dominic A; Martini, Ross P; Ward, Jonathan P et al. (2015) Protective role of p450 epoxyeicosanoids in subarachnoid hemorrhage. Neurocrit Care 22:306-19
Zuloaga, Kristen L; Zhang, Wenri; Yeiser, Lauren A et al. (2015) Neurobehavioral and imaging correlates of hippocampal atrophy in a mouse model of vascular cognitive impairment. Transl Stroke Res 6:390-8
Young, Jennifer M; Nelson, Jonathan W; Cheng, Jian et al. (2015) Peroxisomal biogenesis in ischemic brain. Antioxid Redox Signal 22:109-20
Nelson, Jonathan W; Zhang, Wenri; Alkayed, Nabil J et al. (2015) Peroxisomal translocation of soluble epoxide hydrolase protects against ischemic stroke injury. J Cereb Blood Flow Metab 35:1416-20
Zhu, W; Dotson, A L; Libal, N L et al. (2015) Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice. Neuroscience 288:112-9
Siler, Dominic A; Berlow, Yosef A; Kukino, Ayaka et al. (2015) Soluble Epoxide Hydrolase in Hydrocephalus, Cerebral Edema, and Vascular Inflammation After Subarachnoid Hemorrhage. Stroke 46:1916-22
Zhu, Wenbin; Casper, Amanda; Libal, Nicole L et al. (2015) Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke. Transl Stroke Res 6:60-8

Showing the most recent 10 out of 65 publications